Business
Grass Registration Study Initiation
Grass Registration Study Initiation.
About this update from Niox Group Plc
[{"type":"text","content":"\n \nRNS Number : 1940Z Circassia Pharmaceuticals Plc 25 May 2016 \n\nCircassia Initiates Grass Allergy Immunotherapy Registration Study\nØ Second allergy programme moves into final phase of clinical testing\nØ Lead programme targeting cat allergy on track to report phase III results Q2 2016\n \nOxford, UK - 25 May 2016: Circassia Pharmaceuticals plc (\"Circassia\" or \"the Company\"; LSE: CIR), a specialty biopharmaceutical company focused on allergy and respiratory disease, today announces the initiation of the registration field study for its novel grass allergy immunotherapy. The study, which will be conducted in over 100 centres in the US, Canada and Europe, will enrol approximately 1,500 subjects. In previous clinical trials the grass allergy product candidate has achieved encouraging results, with the optimal regimen demonstrating efficacy in subjects who were followed over three grass pollen seasons after completing the short-course treatment before the start of the first season. \n \nPrincipal Investigator, Professor of Medicine, David Bernstein MD, University of Cincinnati College of Medicine, said: \"Grass pollens are a major cause of seasonal allergies, and associated nasal and eye allergic symptoms can significantly impact allergy patients' quality of life, work or school performance and social functioning. Circassia's investigational new treatment represents an exciting novel therapeutic approach, which previous studies suggest may induce sustained long-term allergen tolerance with a short course of therapy. We look forward to undertaking this large-scale field study to confirm the potential role this promising short-course immunotherapy can play in treating grass allergy.\"\n \nSteve Harris, Circassia's Chief Executive, commented: \"The start of this registration study represents an important milestone for Circassia as we progress our second novel allergy treatment into the final phase of clinical testing. Grass allergy is extremely common, affecting millions of people around the world. However, there is currently no short, simple, long-lasting treatment approved, and we believe our next generation immunotherapy has the potential to address this significant unmet need. We also believe our technology has the potential to revolutionise allergy treatment ...